RECRUITINGINTERVENTIONAL

Search for Diagnostic and Prognostic Biomarkers in Systemic Sclerosis and Inflammatory Myopathies

Search for Diagnostic and Prognostic Biomarkers (Molecular Signatures) in Systemic Sclerosis and Inflammatory Myopathies by a Multi-OMIC Strategy Integrating a Single Cell Analysis Approach

About This Trial

Systemic sclerosis and inflammatory myopathies, which sometimes combine (scleromyositis), have shared pathophysiological elements. In both diseases, many cell subtypes are involved in damage to organs such as T lymphocytes, B lymphocytes, and unconventional (non-B, non-T) lymphocytes called innate lymphoid cell (ILC). The increasing complexity of our understanding of the immune system (multiplication of recognized cell subtypes) also makes the strategies for analyzing pathophysiological mechanisms more complex. Currently, no biomarker perfectly predicts the phenotype and evolution of patients. Multi-OMIC analyzes will be performed (identification of cell populations as well as genomic, transcriptomic and proteomic characterization) in blood and tissue samples (skin and muscle biopsy) in patients with systemic sclerosis and inflammatory myopathies, with the objective of identifying discriminating molecular signatures (biomarkers) according to the characteristics of the disease and its evolution.

Who May Be Eligible (Plain English)

Who May Qualify: - Control population without inflammatory myopathy (population 1), suspected myopathy for whom a blood test and muscle biopsy are required to confirm the diagnosis - Confirmed inflammatory myopathy (population 2) - Control population without systemic sclerosis (population 3), with primary Raynaud's phenomenon - Early diffuse systemic cutaneous scleroderma (population 4) - Male or female (age ≥ 18, no upper age limit) Who Should NOT Join This Trial: Populations 1 \& 2 - Contraindication to muscle biopsy - Diagnosed for another neuromuscular disease - Taking an immunosuppressant / immunomodulator treatment within 3 months before inclusion - Unbalanced cardiovascular pathology Population 3 \& 4 - Contraindication to skin biopsy - Capillaroscopic and / or immunological anomaly suggesting scleroderma - Suspicion of scleroderma but diagnosed for another connectivitis - Immunosuppressive treatment (corticosteroids\> 15 mg, methotrexate, mycophenolate mofetil) introduced for more than 1 month - Active or recent cancer \<3 years (apart from non-melanoma skin cancer). For all \- Pregnancy or breast feeding Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Control population without inflammatory myopathy (population 1), suspected myopathy for whom a blood test and muscle biopsy are required to confirm the diagnosis * Confirmed inflammatory myopathy (population 2) * Control population without systemic sclerosis (population 3), with primary Raynaud's phenomenon * Early diffuse systemic cutaneous scleroderma (population 4) * Male or female (age ≥ 18, no upper age limit) Exclusion Criteria: Populations 1 \& 2 * Contraindication to muscle biopsy * Diagnosed for another neuromuscular disease * Taking an immunosuppressant / immunomodulator treatment within 3 months before inclusion * Unbalanced cardiovascular pathology Population 3 \& 4 * Contraindication to skin biopsy * Capillaroscopic and / or immunological anomaly suggesting scleroderma * Suspicion of scleroderma but diagnosed for another connectivitis * Immunosuppressive treatment (corticosteroids\> 15 mg, methotrexate, mycophenolate mofetil) introduced for more than 1 month * Active or recent cancer \<3 years (apart from non-melanoma skin cancer). For all \- Pregnancy or breast feeding

Treatments Being Tested

OTHER

Collection of biological samples

Skin, muscle fiber and blood sampling

Locations (1)

University Hospital of Hautepierre

Strasbourg, Bas-Rhin, France